ImmunoMet Therapeutics

9 articles about ImmunoMet Therapeutics

• ImmunoMet Therapeutics Announces First Patient Dosed in a Phase 1b Trial of IM156 in Pancreatic Cancer

  11/17/2022

  ImmunoMet Therapeutics, Inc., a clinical stage biotechnology company targeting metabolism to develop novel anti-cancer and anti-fibrotic therapies, today announces that the first patient has been dosed in the single-arm Phase 1b trial of IM156 in combination with gemcitabine and nab-paclitaxel as frontline therapy in patients with advanced pancreatic cancer.

• Dr. Revati Shreeniwas Joins ImmunoMet Therapeutics as Chief Medical Officer

  7/26/2021

  ImmunoMet Therapeutics, Inc., a clinical stage biotechnology company targeting metabolism to develop novel anti-fibrotic and anti-cancer therapies, today announced that Dr. Revati Shreeniwas has joined the company as Chief Medical Officer.

• ImmunoMet Therapeutics Granted Fast Track Designation by U.S. FDA for IM156 in Idiopathic Pulmonary Fibrosis

  5/3/2021

  ImmunoMet Therapeutics, Inc., a clinical stage biotechnology company targeting metabolism to develop novel anti-fibrotic and anti-cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its lead compound IM156, an investigational Protein Complex 1 (PC1) inhibitor, being evaluated for idiopathic pulmonary fibrosis (IPF).

• ImmunoMet Therapeutics Receives IND Clearance and Orphan Drug Designation from U.S. FDA for IM156 in Ideopathic Pulmonary Fibrosis and Completes Financing

  2/8/2021

  - Phase 1 clinical study recruitment in healthy volunteers is expected to start in Q1 2021 - - Pre-clinical studies have demonstrated a strong anti-fibrotic effect in animal models of fibrosis - - Recently completed Phase 1 trial in oncology patients demonstrated good safety profile -

• ImmunoMet Appoints Vincent J. O'Neill, M.D., B.Sc., M.R.C.P, as CMO, and Allan L. Shaw as CFO

  2/12/2018

  Dr. O'Neill, a medical oncologist, joins ImmunoMet with 16 years of oncology therapeutic and diagnostic product development experience at both large pharma and biotech companies.

• ImmunoMet Appoints Briggs W. Morrison, M.D., and Paul Lammers, M.D., M.Sc., to Board of Directors

  11/28/2017

  Dr. Morrison currently serves as the CEO and is a member of the board of directors of Syndax.

• ImmunoMet Appoints Benjamin R. Cowen, PhD, MBA, as CEO

  11/1/2017

  ImmunoMet Therapeutics today announced the appointment of Benjamin R. Cowen, PhD, MBA, as CEO, effective November 1, 2017.

• ImmunoMet Therapeutics Announces Initiation Of Phase I Clinical Study Of IM156, An OXPHOS Inhibitor, In Patients With Solid Tumors

  10/3/2017

• ImmunoMet Therapeutics Raises $5 Million in a Series B Financing

  3/8/2017